Auxergen is a Qualified Maryland Biotech Company designated by the State of Maryland. Auxergen applies engineered bacteriophages as biocontrol reagents for plant diseases and for human and environmental health. (1) We have independently published three virology papers related to plant pathogens (bamboo mosaic virus, citrus canker, rice blight). (2) We have two patents (one issued, one pending) of our phage-based technology against plant Xylella (olive quick decline syndrome) and Xanthomonas diseases. (3) We have developed and licensed cell-based assays to analyze pharmacokinetics of cannabinoid compounds. (4) Since early 2020, we published five research articles of SARS-CoV-2 virus etiology, epidemiology, and evolution in cases. We are the first group to identify RNA recombination of SARS-CoV-2 and investigating COVID-19 viral evolution in a close environment. (5) In December 2023 and January 2024 we presented 3 new papers on filamentous phages.